Key Highlights
- 13.3% was the gain in Picard Medical (NYSEAMERICAN:PMI) to USD 9.90, a rise of USD 1.16 from USD 8.74, simple arithmetic on published figures, not the 15.3% in some early reports.
- USD 1.0 million of 3.0% convertible notes, issued September 30, 2026 and disclosed in an October 6 filing, can convert at the higher of USD 4.00 or the prior day close.
- USD 1.2 million of first quarter 2026 revenue, up 85%, came with a net loss of USD 7.6 million, so growth has not yet covered the cost of running the business.
- 89.1% was the year to date decline in the shares despite a 129.7% gain over the past month, published market data show, a swing that signals very high volatility.
The Move and the Convertible Note Filing
Published market data show Picard Medical (NYSEAMERICAN:PMI) rising about 13.3% to USD 9.90, versus the 15.3% in some early reports. The exact session is uncertain: another quote page showed USD 8.67 at 1:47 p.m. ET on October 7, 2026, so the USD 9.90 level may belong to October 6. The company filing, an 8-K dated October 6, 2026, disclosed USD 1.0 million of convertible notes sold to three accredited investors at 3.0% interest, maturing September 30, 2027. Some early summaries called the attached instruments Equity warrants. The filing describes pre-funded warrants at an exercise price of USD 0.0001. It does not say how the USD 1.0 million of proceeds will be used, and no Going Concern language appeared in it.
How the Notes Convert and Why It Matters
Each note converts at the higher of USD 4.00 or the closing price the day before the conversion notice. At the USD 4.00 floor, the notes would convert into at most 250,000 shares plus shares for accrued interest. For every share issued, the holder also receives a pre-funded Warrant for one more share, exercisable 60 days after issuance with a two-year term. Because the warrants cost almost nothing to exercise, the economic share count could be roughly double. If the 2,055,277 share count in published market data is right, 250,000 shares would be about 12%, simple arithmetic. NYSE American rules cap issuance at 19.99% of shares without Shareholder approval, which limits conversions.
Risks, Peers and What to Watch
Picard Medical makes the SynCardia Total Artificial Heart, and the company reported a May 2026 offering that raised USD 5.0 million. It also reported a NYSE American stockholders' equity deficiency, with a compliance plan accepted in August and a deadline in November 2027, and a 1-for-50 reverse split announced in July. Losses are deep, with a net Margin near negative 444%. Peer PAVmed (NASDAQ:PAVM) rose 3.7% in the same data. Revenue for fiscal 2025 was about USD 4.9 million against a net loss of USD 27.0 million, as reported. Investors should watch conversion notices, any further financing and the second quarter report, whose date the company has not announced in the material reviewed.
Where Things Stand
Picard Medical (NYSEAMERICAN:PMI) rose about 13.3%, not 15.3%, based on the USD 1.16 gain from USD 8.74 to USD 9.90, and the only company item found was the small convertible note financing. The notes add dilution mechanics rather than a clear operating catalyst, and the filing does not explain how the USD 1.0 million will be used. With a Market Value near USD 20 million, simple arithmetic on 2,055,277 shares, and deep losses, one strong session does not change the funding picture.






Please wait processing your request...